PMGC Holdings Inc. (ELAB) Stock

PMGC Holdings Inc. (ELAB) is a Healthcare stock trading at $6.60 (as of 2026-08-21), with a market capitalization of $5.34M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

PMGC Holdings Inc. is a biopharmaceutical company focused on developing and acquiring aesthetic and therapeutic medicines. Its activities include medical research and development and operating investment firms, and it lists EL-22, an engineered probiotic approach intended to support muscle preservation during weight-loss treatments such as GLP-1 receptor agonists.

Understand PMGC Holdings Inc.: how it makes money

PMGC Holdings develops and acquires aesthetic medicines and therapeutic products, with R&D activities centered on its lead product EL-22, and it also operates investment firms.

The profit model is structurally tied to whether its developed and acquired biopharmaceutical products, led by EL-22, progress into meaningful commercial outcomes, while its investment-firm operations can add financial variability.

Business quality (Weak): The provided dataset includes limited company-level financial detail (gross margin only) and no reportable segments or operational KPIs, so it is hard to assess performance drivers beyond EL-22 and the stated product and R&D focus.

Bull case

  • Targeted product focus (EL-22): EL-22 is described as a first-in-class engineered probiotic approach intended to address obesity by preserving muscle during weight loss treatments, including GLP-1 receptor agonists.
  • Platform breadth across product types and R&D: The company focuses on the development and acquisition of aesthetic medicines and therapeutic products, alongside medical scientific research and development activities.

Bear case

  • Execution and commercialization uncertainty: The facts emphasize development and acquisition, with no provided evidence of commercialization metrics, making timing and outcomes of product progress a key risk.
  • Investment-firm operations may introduce volatility: The company operates investment firms, but the provided facts do not break out how those operations perform, which can make results harder to predict.
  • Limited measurable operating signals in the provided data: No operational KPIs or reportable segments are provided, and operating margin is not provided in the dataset.
Valuation — source: SEC EDGAR (first-party)
Price$6.60
Market Cap$5.34M
Price / Book0.32
Price / Sales2.13
FCF Yield-128.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$590084.00
Net Margin-1313.0%
Revenue Growth (YoY)3477.1%
Financial Health — source: SEC EDGAR
Altman Z-Score-3.04 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderCITADEL ADVISORS LLC ($38506.00)
Institutional Holders Tracked4
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOGraydon Bensler
Employees2
CountryUS
IPO Date2023-11-21

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • CNS Pharmaceuticals, Inc. (CNSP)
  • GeoVax Labs, Inc. (GOVX)
  • Xenetic Biosciences, Inc. (XBIO)
  • Exicure, Inc. (XCUR)
  • Apimeds Pharmaceuticals US, Inc (APUS)
  • Enveric Biosciences, Inc. (ENVB)
  • Processa Pharmaceuticals, Inc. (PCSA)
  • AEON Biopharma, Inc. (AEON)
ELAB earnings history · ELAB institutional & insider holders · ELAB KPIs & operating metrics · ELAB financials · ELAB investor presentations & press releases · ELAB SEC filings · ELAB peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.